Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types

AIMS: Programmed death-1/programmed death ligand 1 (PD-1/PD-L1) inhibitor therapy is accompanied by companion or complementary PD-L1 testing in some tumour types. We investigated utilisation of the Dako PD-L1 IHC 28-8 and 22C3 pharmDx assays and the Ventana PD-L1 (SP142) assay and evaluated concorda...

Descripción completa

Detalles Bibliográficos
Autores principales: Krigsfeld, Gabriel S, Prince, Emily A, Pratt, James, Chizhevsky, Vladislav, William Ragheb, Josette, Novotny Jr, James, Huron, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513267/
https://www.ncbi.nlm.nih.gov/pubmed/32591352
http://dx.doi.org/10.1136/jclinpath-2020-206466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513267/
https://www.ncbi.nlm.nih.gov/pubmed/32591352
http://dx.doi.org/10.1136/jclinpath-2020-206466

Ejemplares similares